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Disease progression of human immunodeficiency virus type 1 
(HIV-1) is delayed by HIV type 2 (HIV-2) in individuals with dual 
HIV-1/HIV-2 infection. The protective mechanisms, however, are 
still to be revealed. In the current study we examined type-spe-
cific and cross-reactive antibody-dependent cellular cytotoxicity 
(ADCC) in HIV-1 and HIV-2 monoinfection or dual infection. 
Of note, intertype cross-reactive antibodies that mediated HIV-1 
envelope glycoprotein (Env)–targeted ADCC were frequently 
identified in HIV-2–infected individuals. Furthermore, the mag-
nitude of HIV-1 cross-reactive ADCC activity during HIV-2 infec-
tions depended on the HIV-1 Env origin and was associated with 
the duration of infection. These results suggest that preexisting 
antibodies against HIV-2, which mediate intertype ADCC, might 
contribute to control of HIV-1 during dual infection.
Keywords. ADCC; HIV-1; HIV-2; HIV-1/HIV-2 dual 
infection; intertype cross-reactive; anti-HIV antibodies.
Both human immunodeficiency virus type 1 (HIV-1) and 
HIV type 2 (HIV-2) may cause AIDS development, if not 
treated. However, HIV-2 is less pathogenic than HIV-1, and 
HIV-2–infected individuals remain asymptomatic longer than 
those with HIV-1 infection [1]. HIV-2 is also less transmissible 
and mostly confined to West Africa [1]. In this region, AIDS de-
velopment is also observed in populations dually infected with 
HIV-1 and HIV-2 [2]. However, our longitudinal studies have 
shown that HIV-2 can delay subsequent HIV-1 disease progres-
sion in individuals with dually HIV-1/HIV-2 infection [3]. The 
mechanisms behind this natural inhibition of HIV-1 disease by 
HIV-2 have yet to be revealed and could have implications for 
future vaccines and therapeutics.
The importance of antibody-dependent cellular cytotoxicity 
(ADCC) for protective immunity has been implicated in HIV-1 
vaccine studies [4]. Moreover, ADCC has been associated with 
the control of HIV-1 and simian immunodeficiency virus (SIV) 
infections, and Fc-receptor engagement has been suggested to 
augment neutralizing antibody effector functions [5]. Similarly 
to HIV-2 neutralizing antibodies [6], intratype ADCC activity 
in serum samples from HIV-2–infected individuals has also 
been shown to be frequent and broad [7, 8].
In the current study, we characterized intratype and inter-
type ADCC activity in plasma samples from HIV-1, HIV-2 and 
dually HIV-1/HIV-2–infected individuals. Robust intratype 
ADCC was observed, independent of type of HIV infection. 
Interestingly, we also identified cross-reactive ADCC targeting 
HIV-1 envelope glycoprotein (Env) in plasma samples from 
HIV-2–infected individuals.
MATERIAL AND METHODS
Study Participants
The study participants were part of a police officer cohort 
in Guinea-Bissau [9]. Blood samples were obtained from 
HIV-1–infected (n = 23), HIV-2–infected (n = 30), or dually 
HIV-1/HIV-2–infected (n  =  9) individuals who were either 
treatment naive or not successfully treated (plasma viral load 
[VL]  >1000 copies/mL). The HIV-2–infected individuals 
included 21 considered aviremic and 9 considered viremic, 
based on the plasma VL quantification limit (75 RNA cop-
ies/mL). Samples from HIV-2–infected individuals receiv-
ing successful antiretroviral therapy (ART) (n = 6) were also 
analyzed. Details on sex, age, CD4+ T-cell levels, and VL can 
be found in Supplementary Table 1. Informed consent was 
obtained from the participants and ethical committees of the 
Ministry of Health in Guinea-Bissau and Lund University, 
Sweden, approved the study.
HIV Status, VL, and CD4+ T-Cell Determinations
Blood sampling and determination of HIV status, absolute 
CD4+ T-cell count, percentage of CD4+ T cells, frequency of 
CD38+HLA-DR+ CD4+ T cells and plasma VL, was performed 
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as described elsewhere [10]. The plasma VL detection limit was 
75 RNA copies/mL for HIV-1– or HIV-2–monoinfected and 
135 RNA copies/mL for dually HIV-1/HIV-2–infected individ-
uals. Infection status of individuals with HIV-2 monoinfection 
was also supported by lack of HIV-1 DNA detection, using 
quantitative polymerase chain reaction primers and probe, as 
described elsewhere [10].
ADCC Assay
The ADCC-GranToxiLux assay (OncoImmunin) was per-
formed as described elsewhere, with minor modifications 
[11, 12]. In brief, CEM.NKRCCR5 cells were labeled with TFL4 
and NFL1 and coated with gp120 Env (Immune Technology) 
of HIV-1 subtype B, LAI; subtype C, ZA1197MB; subtype 
CRF02_AG, 01CM_0002BBY (BBY), 1475MV or 98US; and 
HIV-2 subtype B UC1 or SIVmac239 (all pretested for the abil-
ity to bind the target cells). The Env concentration (0.01 mg/
mL for ZA1197MB and BBY; 0.02 mg/mL for LAI; 0.08 mg/mL 
for 1475MV, 98US, UC1 and SIVmac239) was based on com-
petition with anti-CD4 (BD Bioscience) as described elsewhere 
[11]. The source of effector cells was peripheral blood mononu-
clear cells, and the effector-target cell ratio was 30:1. 
Plasma samples from the study subjects (heat inactivated 
for 1 hour), the HIV-1 control immunoglobulin (National 
Institutes of Health AIDS Research and Reagent Program), 
the HIV-2 control SSI 2335 (in-house) and negative control 
(in-house pool of HIV-negative serum samples) were tested in 
5-fold dilutions starting at 1:300. The thresholds for positive 
granzyme B responses were established using HIV-seronegative 
plasma samples (n = 28), including samples from seronegative 
individuals (n = 10) within the study cohort, and were defined 
as the mean plus 3 standard deviations. Thresholds for LAI, 
ZA1197MB, BBY, 1475MV, 98US, UC1, and SIVmac239 were 
5.8, 9.4, 8.5, 6.7, 8.0, 8.0, and 5.7%, respectively. The ADCC 
activity was assessed as the peak percentage of granzyme B–
positive (%GzB+) targets, as well as the area under the curve 
(AUC), and normalized to respective positive control to over-
come day-to-day variations.
Statistical Analysis
Nonparametric statistical analysis for comparison between 
groups (2 or more) and correlations were performed using 
GraphPad Prism software (version 7.0; GraphPad) and included 
Mann-Whitney U and Kruskal-Wallis tests and Spearman rank 
correlation.
RESULTS
Robust Intratype ADCC Activity Frequently Found in Both HIV-1 and HIV-2 
Infections
To investigate HIV-1 and HIV-2 intratype and intertype ADCC, 
plasma samples from HIV-1 (n = 23), HIV-2 (n = 30) or dually 
HIV-1/HIV-2 (n  =  9) infected individuals, either treatment 
naive or not successfully treated, were tested in the ADCC-
GranToxiLux assay [11]. CEM.NKR.CCR5 target cells were coated 
with gp120 originating from HIV-1 subtype CRF02, BBY, or 
HIV-2, UC1. Intratype ADCC, assessed as peak %GzB+ tar-
gets, was demonstrated in plasma samples from all HIV-1 and 
HIV-2–infected individuals. The median percentage was 24.7 
(interquartile range [IQR], 18.4–33.3) and 28.8 (21.4–33.7) 
respectively (Figure 1A and 1B). Plasma samples of  dually 
infected individuals displayed ADCC reactivity against both 
HIV-1 and HIV-2 Env–coated targets.
Cross-Reactive HIV-1 Env–Targeted ADCC Activity Identified in HIV-2–
Infected Individuals
Further analyses revealed that most of the HIV-2–infected indi-
viduals (27 of 30) had plasma with cross-reactive ADCC against 
HIV-1 BBY Env–coated targets, median 20.4 (IQR, 10.7–26.0) 
%GzB+ cells (Figure 1A). On the contrary, intertype ADCC 
against the HIV-2 UC1 Env–coated targets in plasma from 
HIV-1–infected individuals was infrequent (7 of 23) and with 
limited magnitude, median 6.1 (IQR, 4.6–10.2) %GzB+ (Figure 
1B). Intertype ADCC assessed according to AUC corroborated 
findings noted for peak %GzB+ targets (Supplementary Figure 
1A and 1B).
Magnitude of HIV-1 Cross-Reactive ADCC is Elevated in Long-Term HIV-2 
Infections
To investigate modulators of intratype and intertype ADCC 
during HIV-2 infection, we divided the group into viremic 
(n = 9) and aviremic (n = 21) individuals. HIV-2–infected indi-
viduals that had successful ART were also included (n = 6). The 
results showed that the strength of intratype ADCC against 
HIV-2 Env did not differ according to level of viremia, or ART 
(Figure 1C). Instead, magnitude of intertype ADCC targeting 
HIV-1 BBY Env tended to be reduced in HIV-2–infected sub-
jects on ART (P = .10; Figure 1D). Assessing ADCC according 
to AUC further supported the finding that viral control during 
ART tends to reduce intertype ADCC, while the intratype activ-
ity is not affected (Supplementary Figure 1C and 1D). Elevation 
of immune activation, detected as frequency of CD4+ T cells 
expressing CD38+HLA-DR+, was also associated with stron-
ger intertype ADCC (P =  .04; r = 0.385; Figure 2A). No such 
correlation was seen for the intratype ADCC (Supplementary 
Figure 2A). 
Because information on duration of infection was avail-
able for 11 of the HIV-2–infected participants, we com-
pared ADCC between those with longer or shorter infection 
duration (mean, 13.5  years). Individuals with longer HIV-2 
infection had intertype ADCC with higher magnitude than 
those with shorter infection (median 24.2 vs 9.8 %GzB+ tar-
gets respectively; P = .03; Figure 2B). The magnitude of intra-
type ADCC did not differ in relation to infection duration 
(Supplementary Figure 2B).
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Strength of Intertype ADCC Activity in HIV-2 Plasma Depends on the Origin 
of Targeted HIV-1 Env
We next analyzed the breadth of intertype ADCC activity in 
plasma samples from HIV-2–infected individuals. Eleven such 
samples with potent ADCC activity against HIV-1 BBY (>20% 
GzB+ targets) were tested against a panel of gp120-coated targets, 
representing HIV-1 subtype B (LAI), subtype C (ZA1197MB), 
subtype CRF02_AG (98US_MSC5007 and 01CM_1475MV) 
and SIVmac239. Eight of the 11 plasma samples from HIV-2–
infected individuals displayed intertype ADCC against addi-
tional (≥1) HIV-1 Env. Three of the samples mediated intertype 
ADCC against all 5 HIV-1 Envs. We also noted that magnitude 
of intertype ADCC varied depending on Env origin, with BBY 
Env–coated targets being the most sensitive and those coated 
with LAI Env the most resistant (median, 25.6 [IQR, 21.2–33.0] 
vs 5.3 [4.4–7.8] %GzB+, respectively; P  <  .001; Figure 2C). 
ADCC targeting SIVmac239 was strong in all 11 plasma sam-
ples tested from individuals with HIV-2 infection (median, 21.5 
[IQR, 15.4–27.3] %GzB+ targets; Figure 2C).
Plasma samples from HIV-1–infected individuals were also 
tested against the panel of Env-coated targets. Again, the cells 
coated with the BBY Env were found to be the most sensitive 
(Supplementary Figure 2C). As for the breadth of HIV-2 inter-
type ADCC, it both correlated with lower CD4+ T-cell level 
(P  =  .004, r  =  −0.8064; Figure 2D) and higher VL (P  =  .03; 
r  =  0.6518; Supplementary Figure 2D), suggesting that pro-
longed HIV-2 infection may trigger broader ability to mediate 
cross-reactive intertype ADCC.
DISCUSSION
We show that robust intratype ADCC can be detected in plasma 
samples from both HIV-1– infected and HIV-2–infected indi-
viduals. ADCC targeted against Env of both HIV-1 and HIV-2 
origin was also detected in individuals with dual HIV-1/HIV-2 
infection. Moreover, the current study reveals that a majority of 
HIV-2–infected individuals harbor antibodies that can medi-
ate intertype cross-reactive ADCC against targets coated with 
a specific HIV-1 Env protein. The magnitude of this HIV-1 
cross-reactive ADCC activity, identified in plasma samples 
from HIV-2–infected individuals, was in the range of that pre-
viously correlated with protective immunity [4]. In addition, 
some HIV-2–infected individuals had ADCC-mediating anti-
bodies broadly cross-reactive against HIV-1 Envs representing 
different subtypes.
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Figure 1. Intratype and intertype antibody-dependent cellular cytotoxicity (ADCC) in human immunodeficiency virus type 1 (HIV-1), HIV type 2 (HIV-2), and dual HIV-1/
HIV-2 infections. ADCC against HIV-1 gp120 01CM_0002BBY (BBY) envelope glycoprotein (Env) (A, D) and HIV-2 UC1 Env–coated CEM.NKRCCR5 target cells (B, C), mediated 
by plasma samples from treatment-naive or unsuccessfully treated HIV-1 (n = 23), HIV-2 (n = 30), and dually HIV-1/HIV-2 (n = 9) infected individuals (A, B) or samples from 
HIV-2–infected individuals, subdivided according to plasma viral load, above (viremic; n = 9) or below (aviremic; n = 21) 75 RNA copies/mL, and HIV-2–infected subjects 
receiving virus-controlling antiretroviral therapy (ART; n = 6) (C, D). Dotted lines indicate the threshold for positive peak percentage of granzyme B–positive (%GzB+). Statistical 
differences were calculated according to nonparametric Kruskal-Wallis analysis with Dunn posttest. *P < .05; ***P < .001; ****P < .0001. 
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In line with the current study, the few previous studies that 
analyzed ADCC in HIV-2 infections also found frequent HIV-2 
intratype ADCC activity [7, 8]. However, unlike in our study, 
intertype cross-reactive ADCC against HIV-1 was not detected 
[7, 8, 13]. This difference may be due to differences between 
assays; previous studies were based on chromium 51 release 
from chronically infected monocytic cells [7, 8, 13], whereas we 
assessed %GzB+ Env–coated CD4+ T cells. Exposure of Env epi-
topes may also differ; for example, epitopes in the CD4-bound 
confirmation have been reported to depend on the level of CD4 
modulation by HIV-1 accessory proteins [5]. 
Another difference between the current study and previous 
ones might be related to Env antigen variation, because earlier 
studies on HIV-1 ADCC activity within HIV-2 serum sam-
ples exclusively used target cells infected with the HIV-1 IIIB 
strain [7, 8, 13], with the exception of 2 serum samples also 
tested against the RF strain [13]. Interestingly, we found that 
cells pulsed with Env originating from the IIIB homolog LAI 
were the most resistant against HIV-2 antibody-mediated inter-
type ADCC. Thus, our results largely reproduce earlier results 
[7, 8] but also for the first time reveal that HIV-2 infection can 
trigger antibodies mediating ADCC against cells presenting 
other HIV-1 Env variants. Interestingly, the strongest HIV-1 
cross-reactive ADCC was seen against targets coated with 
one of the Envs originating from CRF02_AG, an HIV-1 sub-
type frequently found in the area of the study participants and 
also suggested to influence the strength of intratype ADCC in 
HIV-1–infected populations in this region [14].
In HIV-1–infected individuals, initially strain-specific 
antibodies evolve over time to acquire neutralization activ-
ity against heterologous HIV-1 variants [15]. In line with this 
observation, our study of a subset of plasma samples, uniquely 
obtained from HIV-2–infected individuals in whom infection 
duration was known, suggests that HIV-1 cross-reactive ADCC 
activity increases with longer HIV-2 infection duration. Also, 
correlations between elevated intertype ADCC and declining 
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Figure 2. Modulators of intertype antibody-dependent cellular cytotoxicity (ADCC) magnitude and breadth in human immunodeficiency virus type 2 (HIV-2) infection. 
Cross-reactive ADCC against envelope glycoprotein (Env)–coated CEM.NKRCCR5 targets, mediated by plasma samples from HIV-2–infected treatment-naive or unsuccessfully 
treated individuals, was analyzed. A, B, Intertype HIV type 1 (HIV-1) gp120 01CM_0002BBY (BBY) directed ADCC activity in plasma samples from HIV-2–infected individuals. 
A, Correlation with the percentage of CD38+HLA-DR+ CD4+ T cells. B, Comparison between shorter (n = 5) and longer (n = 6) durations of infection, with the cutoff considered 
the mean duration (13.5 years), as estimated from the midpoint between the last HIV-2 seronegative and the first seropositive samples. C, D, Plasma samples from HIV-2–
infected individuals (n = 11), selected on the basis of having >20% granzyme B–positive (GzB+) HIV-1 BBY Env–coated targets, tested against an extended panel of targets 
pulsed with Env of HIV-1 BBY, ZA1197MB, 98US, 1475MV, LAI, HIV-2 UC1, and SIVmac origin. C, ADCC activity depicted with symbols specific to each study participant). D, 
Correlation between breadth of HIV-1 cross-reactive ADCC, as assessed against the 5 HIV-1 Envs (ie, breadth of 1 indicates ADCC against all 5 Env-coated targets), in relation 
to CD4+ T-cell count. Dotted lines represent the threshold for positive peak percentage of GzB+ targets (%GzB+). Statistical correlations were calculated using nonparametric 
Spearman rank correlations, and differences between 2 groups using the Mann-Whitney U test. *P < .05. 
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CD4+ T-cell counts, as well as elevated frequencies of activated 
CD4+ T cells, imply that prolonged infection duration stimu-
lates development of cross-reactive antibodies. 
In addition, because plasma samples from HIV-2–infected 
individuals receiving ART tended to mediate weaker intertype 
ADCC, the level of virus replication may influence produc-
tion of such antibodies. This has also been noted for intratype 
ADCC in HIV-1–infected individuals during ART [12]. On 
the other hand, the ability to mediate ADCC also depends on 
natural killer cell function, which improves during ART [12]. 
Still, we did not find any statistically significant difference in 
cross-reactive activity between plasma samples from viremic 
and aviremic HIV-2–infected subjects. Thus, low-level viremia 
seems to sustain cross-reactive antibody producing B-cells in 
HIV-2 infection. Intriguingly, we did not find any correlation 
between level of HIV-2 intratype ADCC and infection duration, 
nor virus replication, which is different from findings described 
elsewhere for HIV-1 intratype ADCC activity [12].
The broad ADCC activity against HIV-1 seen in plasma 
samples from HIV-1–infected, as well as some HIV-2–infected 
individuals, is encouraging in the light of vaccine develop-
ment. Antibody responses cross-reactive between different 
HIV-1 strains are essential for an effective vaccine, and broad 
ADCC responses have been associated with virus control 
[5]. Furthermore, our results suggest that intertype ADCC-
mediating antibodies that preexist in HIV-2 infection, at least 
in part, may contribute to reported delay in HIV-1 disease pro-
gression during dual infection [3]. Thus, this observation could 
have implications for the design of HIV disease–preventing 
interventions.
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